Hadassah

Clinical Trial Begins at Hadassah University Medical Center with New Drug to Treat Stroke

Monday, Oct 24 2011

Clinical Trial Begins at Hadassah University Medical Center with New Drug To Treat Stroke. A Phase IIa clinical trial with a medicine to treat ischemic stroke has begun at the Hadassah University Medical Center, based on the research of Prof. Abd Al-Roof Higazi, head of the Department of Clinical Biochemistry at Hadassah Hospital Ein-Kerem.

The safety and clinical effectiveness of THR-18, a product of Thrombotech, will be tested on patients with ischemic stroke in seven medical centers throughout Europe, India, and Israel. Thrombotech Technologies Ltd. is a Portfolio Company of Clal Biotechnology Industries Ltd., Israel's largest active life sciences investment company, and Hadasit Bio-Holdings Ltd., a publicly traded subsidiary of Hadasit, Hadassah's technology transfer company, with biotech products all based on intellectual property developed and owned by the Hadassah University Medical Center.

Approximately 25 patients will be divided into three groups. One group will receive the currently used medication for treating ischemic stroke--tPA--and the other two groups will be treated with THR-18, in two different doses, in combination with tPA. Plans are for an evaluation of the trial to be completed within a year.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Feb 14 2018

Student with MS Running the Jerusalem Marathon to Support Hadassah’s MS Program

Thanks to his physicians at the Hadassah Medical Center, Dov Guggenheim, who was diagnosed with Multiple Sclerosis (MS) in 2015, has gone from “depressed to optimistic, paralyzed to athletic, and, most important, hopeless to hopeful.”

READ MORE ›
alt_text

Wednesday, Feb 7 2018

Texas Tropical Disease Expert Meets with Hadassah Infectious Disease Specialists

Dr. Peter Jay Hotez, renowned professor in the Departments of Pediatrics and Molecular Virology and Microbiology at Houston (Texas) Baylor College of Medicine and Dean of its National School of Tropical Medicine, met with two Hadassah Medical Organization infectious disease specialists to discuss regional cooperation in fighting tropical diseases, such as the now-infamous Zika virus and leishmaniosis, which is contracted from sand flies.

READ MORE ›
alt_text

Wednesday, Feb 7 2018

Large Hadassah Study Identifies Predictor of Greater Risk of End-Stage Renal Disease

The findings of a nationwide study of over a million and a half Israeli adolescents, conducted by researchers at the Hadassah-Hebrew University Braun School of Public Health and Community Medicine, suggest that kidney disease in childhood is associated with a significantly increased risk of end-stage renal disease (ESRD) in adulthood, even if kidney function seems normal in adolescence.

READ MORE ›
alt_text

Wednesday, Feb 7 2018

Israeli Start-up’s Algorithm Predicts Which Diabetic Patients Will Suffer Kidney Dysfunction Within One Year

The Israeli start-up Medial EarlySign has created a machine-learning-based model that has proven to identify diabetic patients who are at the highest risk for experiencing renal dysfunction within one year.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More